Artificial Intelligence (AI) in Pathology Market Summary

• The AI in Pathology market is estimated at USD 0.13 billion in 2025 and is projected to reach USD 0.95 billion by 2034. Growth is anchored in the rising global cancer burden, a worsening shortage of pathologists, and a wave of FDA-cleared AI software that automates cancer detection, grading, and biomarker quantification on digitized slides.

• The global AI in Pathology market is growing at a CAGR of 24.7% during the forecast period from 2026 to 2034.

• By offering, the software segment dominated the AI in Pathology market with a 51% share in 2025.

• By technology, the machine learning segment dominated the AI in Pathology market with a 45% share in 2025.

• By application, the disease diagnosis segment dominated the AI in Pathology market with a 58% share in 2025.

• By end user, the hospitals and reference laboratories segment dominated the AI in Pathology market with a 47% share in 2025.

• North America dominated the global AI in Pathology market revenue with a 41% share in 2025, representing the highest regional market share globally.

Artificial intelligence (AI) in pathology refers to the application of machine learning, deep learning, and computer vision to digitized tissue and cytology specimens to assist in the detection, grading, quantification, and interpretation of disease. Building on the digital-pathology foundation of whole-slide imaging scanners and image management systems, AI algorithms analyze high-resolution slide images to flag suspicious foci, score immunohistochemistry and biomarkers, quantify tumor features, support companion diagnostics, and optimize workflow through case triage, quality control, and digital reporting. The market combines software, including algorithms and image-management platforms, with hardware such as scanners and computing infrastructure, and services spanning deployment, integration, and managed analytics. Core technologies include convolutional and other neural networks, computer vision, and emerging generative and foundation models trained on millions of slides. Applications span anatomic pathology in oncology and non-oncologic disease, companion diagnostics, telepathology, biomarker-driven precision medicine, and pharmaceutical research. Accelerated by a wave of FDA authorizations, EU IVDR certifications, and large foundation-model and consolidation moves, AI has become the most transformative force in modern pathology, shifting the field from glass slides toward computational, data-driven diagnosis.

AI in Pathology Market Key Growth Drivers

• The rising global cancer burden is increasing biopsy and slide volumes, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.

• A worsening global shortage of pathologists, combined with rising caseloads, is driving adoption of AI that automates detection, grading, and quantification to improve throughput and consistency.

• Accelerating regulatory clearances are building clinical trust, with FDA authorizations for AI pathology rising to ten in 2025 and EU IVDR certifications expanding market access.

• The transition from glass slides to digital pathology and whole-slide imaging is creating the data foundation on which AI algorithms operate at scale.

• The emergence of foundation models and generative AI co-pilots, trained on millions of slides, is expanding capability across cancer detection, biomarker discovery, and reporting.

• Growing demand for precision oncology, companion diagnostics, and biomarker quantification is driving pharmaceutical and clinical adoption of AI pathology.

• The convergence of cancer burden, workforce shortage, digitization, regulatory support, and foundation models is expected to sustain rapid growth in the market through 2034.

Key Companies in AI in Pathology Market

The competitive landscape is led by the following active developers and providers:

• Tempus AI, Inc. (Paige)

• F. Hoffmann-La Roche Ltd

• Koninklijke Philips N.V.

• PathAI, Inc.

• Ibex Medical Analytics Ltd.

• Proscia Inc.

• Indica Labs, Inc.

• Aiforia Technologies Plc

• Hologic, Inc.

• Visiopharm A/S

Factors Contributing to the Growth of the AI in Pathology Market

Market Drivers

Rising Global Cancer Burden and Slide Volumes

The most powerful driver of the AI in Pathology market is the rising global cancer burden, which increases biopsy and slide volumes and the complexity of diagnosis. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and the incidence of common malignancies such as prostate cancer is expected to rise sharply, with global prostate cancer cases projected to double by 2040. Each cancer workup generates tissue and cytology slides that must be examined, graded, and characterized, and precision-oncology and companion-diagnostic workflows add biomarker and immunohistochemistry scoring. AI in pathology directly addresses this growing workload by detecting suspicious foci, grading tumors, and quantifying biomarkers with speed and consistency. As cancer incidence climbs and diagnostic complexity deepens, demand for AI that augments pathologists expands, anchoring market growth through 2034.

Worsening Shortage of Pathologists and Rising Caseloads

A worsening global shortage of pathologists, combined with rising caseloads, is a central driver of AI adoption. The supply of trained pathologists is growing far more slowly than demand, producing backlogs, longer turnaround times, burnout, and variability in interpretation, with shortages especially acute outside major academic centers and in lower-resource regions. AI in pathology mitigates this gap by automating repetitive detection and measurement tasks, triaging cases, generating draft quantification, and acting as a diagnostic safety net that flags small or rare cancers a pathologist might miss. By improving throughput, consistency, and access without proportionally increasing staffing, AI delivers clear operational value to hospitals and reference laboratories handling the largest case volumes. This structural workforce pressure reinforces demand for AI augmentation across clinical and reference settings throughout the forecast period.

Market Restraints

Despite strong momentum, the AI in Pathology market faces material constraints. High capital requirements are a significant barrier, as the transition to digital and AI-enabled pathology demands whole-slide imaging scanners, storage and computing infrastructure, and integration with laboratory systems, costs that are difficult for smaller and lower-resource laboratories to absorb. Regulatory and clinical-validation requirements add complexity, as AI diagnostic tools must demonstrate clear clinical benefit and navigate evolving FDA and EU IVDR frameworks, lengthening development timelines and requiring ongoing post-market performance monitoring. A shortage of skilled professionals able to develop, validate, and operate AI systems constrains deployment, with surveys indicating most organizations struggle to find qualified AI talent. Interoperability and standardization gaps between scanners, image formats, and AI platforms complicate integration and reproducibility, and the persistence of proprietary formats slows scalability. Clinician trust remains a gating factor, as concerns about algorithmic bias, generalizability across diverse populations, and accountability for AI-influenced diagnoses require transparency and robust validation. Reimbursement for AI-enabled pathology remains uneven and immature across geographies, constraining return on investment, while data-privacy, governance, and cybersecurity obligations involving large slide datasets add burden. Together, these capital, regulatory, workforce, interoperability, trust, and reimbursement barriers temper the pace of growth, even as the underlying drivers of cancer burden, workforce shortage, and digitization remain firmly intact.

AI in Pathology Market Segment Analysis

The AI in Pathology Market by Offering (Software, Hardware, Services), Technology (Machine Learning, Deep Learning, Computer Vision, Generative and Foundation Models, Others), Application (Disease Diagnosis and Prognosis, Drug Discovery and Development, Companion Diagnostics, Workflow and Quality Control, Others), End User (Hospitals and Reference Laboratories, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Offering

Dominant Subsegment: Software. The software category is expected to dominate the market.

Dominant:  Software ~ 51%

The software segment accounted for 51% of the AI in Pathology market in 2025. Software is the leading offering because the value of AI in pathology resides in the algorithms and image-management platforms that detect cancer, grade tumors, quantify biomarkers, and orchestrate workflow, and because software generates recurring revenue through licenses, subscriptions, and cloud services. Cloud-native image management systems that unify slide viewing, collaboration, and integrated AI, such as enterprise platforms deployed across hospital networks, anchor the segment, while clinically validated algorithms address detection, grading, and biomarker scoring. FDA-cleared software and image-management stacks are normalizing multi-AI workflows, allowing laboratories to add modules over time and expanding software spend across the installed base. The shift toward foundation models trained on millions of slides deepens the software tier further by enabling broad, generalizable capabilities. Because algorithms improve continuously and scale without proportional hardware, software commands the largest and most durable share, while hardware such as scanners provides the imaging substrate and services support deployment, integration, and managed analytics.

By Technology

Dominant Subsegment: Machine Learning. The machine learning category is expected to dominate the market.

Dominant:  Machine Learning ~ 45%

The machine learning segment accounted for 45% of the AI in Pathology market in 2025. Machine learning is the leading technology because it underpins the majority of deployed AI pathology applications, with convolutional and other neural networks trained on annotated whole-slide images powering cancer detection, grading, and biomarker quantification. Trained on large labeled datasets, machine-learning models deliver the pattern-recognition capabilities that pathologists rely on, and they form the foundation on which deep learning, a specialized subset, extends performance for complex histopathology. The segment's dominance reflects maturity, regulatory familiarity, and broad integration across cleared clinical tools from Tempus' Paige, Ibex, and others. Adjacent technologies are advancing quickly: computer vision powers image analysis and is among the fastest-growing approaches, while generative and foundation models trained on millions of slides are expanding rapidly for biomarker discovery and diagnostic co-pilots. While these newer approaches grow fast from smaller bases, machine learning retains leadership in 2025 through its breadth of validated, deployed clinical applications across the installed base.

By End User

Dominant Subsegment: Hospitals and Reference Laboratories. The hospitals and reference laboratories category is expected to dominate the market.

Dominant:  Hospitals and Reference Laboratories ~ 47%

The hospitals and reference laboratories segment accounted for 47% of the AI in Pathology market in 2025. Hospitals and reference laboratories are the largest end user because they process the highest volume of pathology cases and have the scale, infrastructure, and clinical breadth to adopt digital pathology and enterprise AI platforms. These facilities anchor the installed base for whole-slide imaging and image-management systems, and they deploy AI to accelerate detection, standardize grading, and manage rising caseloads amid pathologist shortages. Large hospital networks and national laboratories are implementing enterprise platforms that unify slide management with integrated AI across many sites, exemplified by health systems and nationwide pathology networks adopting cloud-native image-management systems. This concentration of volume and infrastructure drives the bulk of AI pathology demand. At the same time, pharmaceutical and biotechnology companies and research and academic institutes are growing quickly as biomarker discovery and clinical-trial applications expand. Nonetheless, the volume, infrastructure, and clinical centrality of hospitals and reference laboratories secure their leadership across the forecast period.

AI in Pathology Market Region Analysis

Dominant Region: North America

North America accounted for 41% of the global AI in Pathology market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high adoption of digital pathology, substantial AI investment, and the most active regulatory environment, particularly in the United States. North America hosts the largest concentration of AI pathology developers, including Tempus, Paige, PathAI, and Proscia, and benefits from a steady cadence of FDA authorizations, with AI pathology clearances rising to ten in 2025 and the FDA issuing clarifying guidance on AI-enabled devices. The region leads in foundation-model development, exemplified by the Tempus acquisition of Paige to build a large oncology foundation model, and in enterprise deployments across hospital and reference-laboratory networks. Strong precision-oncology and companion-diagnostic programs, deep venture and strategic investment, and integration with electronic health records reinforce adoption. A dense developer base, regulatory clarity, and digitized infrastructure anchor the region's continued leadership.

Dominant:  North America ~ 41% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the AI in Pathology market. The region's elevated CAGR is driven by a large and rising cancer burden, an acute shortage of pathologists relative to population, expanding healthcare investment, and rapid digitization across China, Japan, India, South Korea, and Australia. Severe pathologist shortages in populous markets make AI augmentation and telepathology especially valuable for extending diagnostic capacity, and active regional developers in China, Korea, and Taiwan are scaling computational pathology platforms. Government digital-health initiatives, growing precision-oncology adoption, and increasing laboratory digitization are accelerating deployment, while lower-cost local solutions broaden access. The combination of high disease burden, workforce constraints, and rapid digitization positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 41% of the global AI in Pathology market revenue in 2025. The United States dominates on the strength of its developer base, high digital-pathology adoption, the most active FDA authorization and guidance environment, leadership in foundation models, and integration with precision-oncology and companion-diagnostic programs, while Canada contributes through hospital and academic adoption.

Europe

Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong public health systems, regional digital-pathology initiatives, and the EU In Vitro Diagnostic Regulation, which raises the evidence bar and, through IVDR certification of leading AI tools, validates clinical performance. A strong base of European developers, including Aiforia, Visiopharm, Mindpeak, and Tribun Health, reinforces the region's position.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a rising cancer burden, acute pathologist shortages, expanding healthcare investment, and rapid digitization across China, Japan, India, South Korea, and Australia. Regional developers in China, Korea, and Taiwan scale computational pathology platforms, while government digital-health programs and telepathology extend diagnostic access across large and underserved populations.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. A rising cancer burden, severe shortages of pathologists, and limited laboratory capacity make AI augmentation and telepathology especially valuable, and government digitization initiatives and partnerships, such as large integrated healthcare networks adopting AI image-management systems, are expanding access across these markets.

AI in Pathology Market Competitive Landscape

The AI in Pathology market is classified as Moderately Concentrated. A group of leading AI pathology developers and diagnostics majors, including Tempus with Paige, Roche, Philips, PathAI, and Ibex, holds substantial share through advanced platforms, clinical collaborations, and regulatory clearances, while a dynamic field of specialized providers such as Proscia, Indica Labs, Aiforia, Visiopharm, Hologic, and Mindpeak competes across image management, biomarker analysis, and specific cancer indications, increasing competition in fast-growing segments.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with leading platform developers and diagnostics majors alongside a fast-growing field of specialized challengers.

• Leading players: Tempus (Paige), Roche, Philips, PathAI, and Ibex anchor the top tier through validated platforms and clearances.

• Geographic reach: Leaders operate global commercial networks, with nationwide pathology networks and partnerships extending into Europe, Latin America, and Asia-Pacific.

• Product portfolio strength: Top players hold integrated portfolios spanning image management, cleared detection and grading algorithms, and biomarker analytics.

• Pipeline strength: Deep pipelines in multi-tissue detection, prognostic and predictive tools, and foundation models, including breakthrough-designated platforms.

• Strategic partnerships: Extensive collaborations, such as Roche with PathAI and Ibex, and Leica Biosystems with Paige, embed AI into diagnostics and scanners.

• M&A activity: Active consolidation, led by Tempus' acquisition of Paige to build a large oncology foundation model.

• Regulatory strength: FDA authorizations and EU IVDR certifications are decisive competitive assets, with clearances rising to ten in 2025.

• Innovation focus: Foundation models, generative AI co-pilots, multi-tissue detection, prognostic and predictive biomarkers, and cloud-native enterprise platforms.

AI in Pathology Market Recent Developmental Activities

In August 2025, Tempus AI, Inc. completed the acquisition of Paige, merging Paige's 7 million digitized slides with Tempus' multiomic data with the stated goal of building the largest foundation model in oncology. Strategic significance: Creates a leading data and foundation-model position and accelerates the path from discovery to regulated AI pathology tools.

In August 2025, PathAI, Inc. (with Moffitt Cancer Center) announced a multi-year strategic partnership to implement the AISight Dx cloud-native digital pathology platform across Moffitt's pathology operations. Strategic significance: Anchors enterprise-scale AI pathology adoption at a leading cancer center and showcases unified slide management with integrated AI.

AI in Pathology Market Segmentation

AI in Pathology Market by Offering

• Software

• Hardware

• Services

AI in Pathology Market by Technology

• Machine Learning

• Deep Learning

• Computer Vision

• Generative and Foundation Models

• Others

AI in Pathology Market by Application

• Disease Diagnosis and Prognosis

▪ Oncology Pathology

▪ Non-Oncologic Pathology

• Drug Discovery and Development

• Companion Diagnostics

• Workflow and Quality Control

• Others

AI in Pathology Market by End User

• Hospitals and Reference Laboratories

• Diagnostic Laboratories

• Pharmaceutical and Biotechnology Companies

• Research and Academic Institutes

• Others

AI in Pathology Market by Geography

• North America AI in Pathology Market

▪ United States AI in Pathology Market Size in USD million (2023-2034)

▪ Canada AI in Pathology Market Size in USD million (2023-2034)

▪ Mexico AI in Pathology Market Size in USD million (2023-2034)

• Europe AI in Pathology Market

▪ Germany AI in Pathology Market Size in USD million (2023-2034)

▪ United Kingdom AI in Pathology Market Size in USD million (2023-2034)

▪ France AI in Pathology Market Size in USD million (2023-2034)

▪ Italy AI in Pathology Market Size in USD million (2023-2034)

▪ Spain AI in Pathology Market Size in USD million (2023-2034)

▪ Rest of Europe AI in Pathology Market Size in USD million (2023-2034)

• Asia-Pacific AI in Pathology Market

▪ China AI in Pathology Market Size in USD million (2023-2034)

▪ Japan AI in Pathology Market Size in USD million (2023-2034)

▪ India AI in Pathology Market Size in USD million (2023-2034)

▪ Australia AI in Pathology Market Size in USD million (2023-2034)

▪ South Korea AI in Pathology Market Size in USD million (2023-2034)

▪ Rest of Asia-Pacific AI in Pathology Market Size in USD million (2023-2034)

• Rest of the World (RoW) AI in Pathology Market

▪ Middle East AI in Pathology Market Size in USD million (2023-2034)

▪ Africa AI in Pathology Market Size in USD million (2023-2034)

▪ South America AI in Pathology Market Size in USD million (2023-2034)

Key Takeaways from the AI in Pathology Market Report Study

• Market size analysis for the current AI in pathology market size (2025), and market forecast for 9 years (2026 to 2034).

• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.

• Key companies dominating the global AI in pathology market.

• Various opportunities available for competitors in the AI in pathology market space.

• What are the top-performing segments in 2025? How will these segments perform in 2034?

• Which are the top-performing regions and countries in the current AI in pathology market scenario?

• Which are the regions and countries where companies should concentrate their opportunities for AI in pathology market growth in the future?

Target audience who can benefit from this AI in pathology market report study

• AI in Pathology product providers

• Research organizations and consulting companies

• AI in Pathology-related organizations, associations, forums, and other alliances

• Government and corporate offices

• Start-up companies, venture capitalists, and private equity firms

• Distributors and traders dealing in AI in pathology

Various end-users who want to know more about the AI in pathology market and the latest technological developments in the AI in pathology market.